4 years ago

Beckley Psytech Secures €49 Million to Advance Psychedelic Medicine Research

  • Beckley Psytech, a British startup using psychedelic medicines to treat neurological and psychiatric disorders, has raised €49 million in a Series B funding round

  • The round was led by healthcare-focused VC firm Integrated, with participation from Prime Movers Labs, Adage Capital Management LP, and others

  • The funding will support ongoing and new clinical trials for treatments using psilocybin and 5-MeO-DMT, as well as the expansion of the company's pipeline with new psychedelic compounds.

      • ProblemHealthcare

      "Millions of people suffer from neurological and psychiatric disorders with limited effective treatment options."

      Solution

      "Beckley Psytech is developing novel psychedelic medicines to treat a range of neurological and psychiatric disorders, including SUNHA and Treatment Resistant Depression."

      Covered on